313 related articles for article (PubMed ID: 18485512)
1. Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity.
Kojima N; Biao L; Nakayama T; Ishii M; Ikehara Y; Tsujimura K
J Control Release; 2008 Jul; 129(1):26-32. PubMed ID: 18485512
[TBL] [Abstract][Full Text] [Related]
2. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells.
Ikehara Y; Shiuchi N; Kabata-Ikehara S; Nakanishi H; Yokoyama N; Takagi H; Nagata T; Koide Y; Kuzushima K; Takahashi T; Tsujimura K; Kojima N
Cancer Lett; 2008 Feb; 260(1-2):137-45. PubMed ID: 18077084
[TBL] [Abstract][Full Text] [Related]
3. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
4. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
5. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
6. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.
Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK
J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124
[TBL] [Abstract][Full Text] [Related]
7. Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study.
Zhou F; Rouse BT; Huang L
Cancer Res; 1992 Nov; 52(22):6287-91. PubMed ID: 1384958
[TBL] [Abstract][Full Text] [Related]
8. Induction of antigen-specific cytotoxic T lymphocytes by immunization with negatively charged soluble antigen through scavenger receptor-mediated delivery.
Yamasaki Y; Ikenaga T; Otsuki T; Nishikawa M; Takakura Y
Vaccine; 2007 Jan; 25(1):85-91. PubMed ID: 16956699
[TBL] [Abstract][Full Text] [Related]
9. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling.
Met O; Wang M; Pedersen AE; Nissen MH; Buus S; Claesson MH
Cancer Lett; 2006 Jan; 231(2):247-56. PubMed ID: 16399226
[TBL] [Abstract][Full Text] [Related]
10. Intranasal immunization with poly(γ-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity.
Matsuo K; Koizumi H; Akashi M; Nakagawa S; Fujita T; Yamamoto A; Okada N
J Control Release; 2011 Jun; 152(2):310-6. PubMed ID: 21402114
[TBL] [Abstract][Full Text] [Related]
11. Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor.
Makki A; Weidt G; Blachere NE; Lefrançois L; Srivastava PK
Cancer Immun; 2002 Apr; 2():4. PubMed ID: 12747749
[TBL] [Abstract][Full Text] [Related]
12. Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP).
Hornung RL; Longo DL; Gowda VL; Kwak LW
Ther Immunol; 1995 Feb; 2(1):7-14. PubMed ID: 7553072
[TBL] [Abstract][Full Text] [Related]
13. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo.
Sheng KC; Kalkanidis M; Pouniotis DS; Esparon S; Tang CK; Apostolopoulos V; Pietersz GA
Eur J Immunol; 2008 Feb; 38(2):424-36. PubMed ID: 18200633
[TBL] [Abstract][Full Text] [Related]
14. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
15. Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap.
Nabekura T; Otsu M; Nagasawa T; Nakauchi H; Onodera M
Mol Ther; 2006 Feb; 13(2):301-9. PubMed ID: 16311073
[TBL] [Abstract][Full Text] [Related]
16. Targeting with oligomannose-coated liposomes promotes maturation and splenic trafficking of dendritic cells in the peritoneal cavity.
Ishii M; Kato C; Hakamata A; Kojima N
Int Immunopharmacol; 2011 Feb; 11(2):164-71. PubMed ID: 21112331
[TBL] [Abstract][Full Text] [Related]
17. Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization.
Ishii M; Kojima N
Glycoconj J; 2010 Jan; 27(1):115-23. PubMed ID: 19816665
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells.
Yoshikawa T; Okada N; Oda A; Matsuo K; Matsuo K; Kayamuro H; Ishii Y; Yoshinaga T; Akagi T; Akashi M; Nakagawa S
Vaccine; 2008 Mar; 26(10):1303-13. PubMed ID: 18255205
[TBL] [Abstract][Full Text] [Related]
19. Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens.
Okada N; Tsujino M; Hagiwara Y; Tada A; Tamura Y; Mori K; Saito T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
Br J Cancer; 2001 Jun; 84(11):1564-70. PubMed ID: 11384109
[TBL] [Abstract][Full Text] [Related]
20. In vivo investigation of twin-screw extruded lipid implants for vaccine delivery.
Even MP; Young K; Winter G; Hook S; Engert J
Eur J Pharm Biopharm; 2014 Jul; 87(2):338-46. PubMed ID: 24607791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
